Combining Shockwave Therapy with Drug-Eluting Stents for Peripheral Artery Disease

Physician-Initiated PMCF Trial Investigating Shockwave Intravascular Lithotripsy and a Drug Eluting Vascular Stent System Deployment for Heavily Calcified Femoropopliteal Disease

This study is testing if combining shockwave therapy with a special stent can help people with blocked leg arteries feel better and improve their blood flow.

Quick facts

• Study type: Observational
• Enrollment: 50 (estimated)
• Ages: 21 Years to 85 Years
• Sex: All
• Sponsor: FCRE (Foundation for Cardiovascular Research and Education) (other)
• Locations: 6 sites (Arnsberg and 5 other locations)
• Trial ID: NCT05291247 on ClinicalTrials.gov

What this trial studies

This clinical investigation aims to assess the safety and efficacy of using Shockwave Intravascular Lithotripsy in conjunction with a polymer-coated Drug Eluting Stent for patients with calcified femoropopliteal disease over a 12-month period. The study focuses on individuals diagnosed with symptomatic peripheral artery disease, specifically those with significant stenosis in the superficial femoral artery and/or proximal popliteal artery. Participants will undergo treatment and be monitored for outcomes related to their vascular health and symptom relief.

Who should consider this trial

Good fit: Ideal candidates are adults aged 21 to 85 with symptomatic peripheral artery disease and significant stenosis in the superficial femoral or proximal popliteal arteries.

Not a fit: Patients with less severe calcification or those not meeting the specific anatomical criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve treatment outcomes for patients with severe calcified peripheral artery disease.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in treating calcified vascular lesions, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

* Subject must be between 21 and 85 years old
* Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5
* Willing to comply with the specified follow-up evaluation
* Written informed consent prior to any study procedures
* Stenotic, restenotic after PTA or occlusive lesion(s) located in the native Superficial Femoral Artery (SFA) and/or proximal Popliteal Artery (PPA):

  1. Degree of stenosis ≥ 70% by visual agiographic assessment
  2. Vessel diameter ≥ 4 and ≥ 6 mm
  3. Total lesion length (or series of lesions) ≥ 30 mm and 210 mm (Note: Lesion segment(s) must be filly covered with one or two overlapping DES stent (s) be fully covered with one or two overlapping DES stent(s)
  4. Target lesion located at least three centimeters above the inferior edge of the femur
* Severity of calcification PACSS 3-4
* Patent infrapopliteal and popliteal artery; i.e. single vessel runoff or better with at least one of three vessels patent (\>50% stenosis) to the ankle or foot with no planned intervention.
* Study entry after successful target lesion crossing of the guidewire (guidewire located intraluminally or subintimally); Both crossing devices as well as retrograde recanalization can be used.
* Non-target lesion interventions to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and should be completed successfully.

Exclusion Criteria:

* Not treated ipsilateral significant (\>50%) stenosis of the iliac arteries
* Non severely calcified disease (absence of calcification, PACSS 1, PACSS 2)
* Significant (\>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot
* Angiographic evidence of thrombus within the target vessel
* Thrombolysis within 72 hours prior to the index procedure
* Previously stented target lesion / vessel
* Subjects who have undergone prior surgery of the target lesion SFA/PPA to treat atherosclerotic disease
* Bypass Anastomosis stenosis
* Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy
* Recent MI or stroke \<30 days prior to the index procedure
* Life expectancy less than 24 months
* Known or suspected active infection at the time of the index procedure
* Known or suspected major allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent
* Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimalparticipation in the study
* The subject is currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
* Female subjects pregnant, breastfeeding, of childbearing potential who are planning to become pregnant in the next 5 years.
* End-stage-renal disease
* Presence of Severe Ischemic Ulcers or frank gangrene (Rutherford class 6).

Where this trial is running

Arnsberg and 5 other locations

• Klinikum Hochsauerland — Arnsberg, Germany (RECRUITING)
• University Hospital Essen — Essen, Germany (RECRUITING)
• University Hospital Eppendorf — Hamburg, Germany (RECRUITING)
• SRH Klinikum Karlsbad-Langensteinbach — Karlsbad, Germany (RECRUITING)
• St. Marien Hospital — Lünen, Germany (NOT_YET_RECRUITING)
• University Hospital LMU Munich — Munich, Germany (RECRUITING)

Study contacts

• Principal investigator: Konstantinos Stavroulakis, MD — Vascular Department, LMU Munich
• Study coordinator: Annelena Held-Wehmöller, PhD

Conditions: Peripheral Arterial Disease, Superficial Femoral Artery Stenosis, Calcifications Vascular